RBC ups Forest target

Forest Laboratories, Inc. was kept at a sector perform, above average risk, rating but with an increased price target of $54 from $48 by RBC Capital Markets analyst Douglas Miehm. The analyst made minor revisions to his model and adjusted the growth of the Lexapro market. The company's second-quarter results and what could be management's conservative guidance are encouraging, according to Miehm. Shares of the New York City-based pharmaceutical company were down $1.69, or 3.20%, at $51.19. (NYSE: FRX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.